• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Sr One Capital Management, Llc claimed ownership of 6,822,114 units of Common Stock

    9/2/21 3:26:25 PM ET
    $LWAC
    Finance
    Get the next $LWAC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    SR ONE CAPITAL MANAGEMENT, LLC

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/25/2021
    3. Issuer Name and Ticker or Trading Symbol
    eFFECTOR Therapeutics, Inc. [ EFTR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 4,822,114(1)(2) I Directly owned by SR One Capital Fund I Aggregator, LP(3)
    Common Stock 2,000,000(1)(4) I Directly owned by SR One Co-Invest I, LLC(5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Earn-out Right (6) (6) Common Stock 605,338 (6) I Directly owned by SR One Capital Fund I Aggregator, LP(3)
    1. Name and Address of Reporting Person*
    SR ONE CAPITAL MANAGEMENT, LLC

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    SR ONE CAPITAL PARTNERS I, LP

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    SR One Capital Fund I Aggregator LP

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    SR One Co-Invest I, LLC

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    SR One Co-Invest I Manager, LLC

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    George Simeon

    (Last) (First) (Middle)
    985 OLD EAGLE SCHOOL ROAD
    SUITE 511

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    Explanation of Responses:
    1. On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.
    2. The securities of the Issuer reported herein are held directly by SR One Capital Fund I Aggregator, LP and includes 4,109,329 shares of common stock that were acquired in the Merger and 712,785 shares of common stock that were acquired in the private placement which closed concurrently with the Merger.
    3. SR One Capital Partners I, LP serves as the general partner of SR One Capital Fund I Aggregator, LP, and SR One Capital Management, LLC serves as the general partner of SR One Capital Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners I, LP, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    4. The securities of the Issuer reported herein are held directly by SR One Co-Invest I, LLC and consist of 2,000,000 shares of common stock that were acquired in the private placement which closed concurrently with the Merger.
    5. SR One Co-Invest Manager I, LLC serves as the manager of SR One Co-Invest I, LLC, and SR One Capital Management, LLC serves as the manager of SR One Co-Invest Manager I, LLC. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Co-Invest I, LLC, SR One Co-Invest Manager I, LLC, SR One Capital Management, LLC and Mr. George may each be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    6. Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023.
    Remarks:
    SR One Capital Management, LLC, By: /s/ Simeon George, Managing Member 09/02/2021
    SR One Capital Partners I, LP, By: SR One Capital Management, LLC, its General Partner, By: /s/ Simeon George, Managing Member 09/02/2021
    SR ONE CAPITAL FUND I AGGREGATOR, L.P., SR One Capital Partners I, LP, its General Partner, By: SR One Capital Management, LLC, its General Partner, By: /s/ Simeon George, Managing Member 09/02/2021
    SR One Co-Invest I, LP, By: SR One Co-Invest Manager I, LLC, its Manager, By: SR One Capital Management, LLC, its Manager, By: /s/ Simeon George, Managing Member 09/02/2021
    SR One Co-Invest Manager I, LLC, By: SR One Capital Management, LLC, its Manager, By: /s/ Simeon George, Managing Member 09/02/2021
    /s/ Simeon George 09/02/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LWAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LWAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LWAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/13/21 6:23:36 AM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/7/21 5:12:00 PM ET
      $LWAC
      Finance
    • SEC Form SC 13D filed by Locust Walk Acquisition Corp.

      SC 13D - eFFECTOR Therapeutics, Inc. (0001828522) (Subject)

      9/3/21 4:00:25 PM ET
      $LWAC
      Finance

    $LWAC
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Locust Walk Acquisition Corp.

      S-1/A - LightWave Acquisition Corp. (0002061379) (Filer)

      6/9/25 8:37:32 AM ET
      $LWAC
      Finance
    • SEC Form EFFECT filed by Locust Walk Acquisition Corp.

      EFFECT - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/6/21 12:15:17 AM ET
      $LWAC
      Finance
    • SEC Form 424B3 filed by Locust Walk Acquisition Corp.

      424B3 - eFFECTOR Therapeutics, Inc. (0001828522) (Filer)

      10/5/21 4:24:26 PM ET
      $LWAC
      Finance

    $LWAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Locust Walk Acquisition Corp.'s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies

      SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Locust Walk Acquisition Corp. (NASDAQ:LWAC) ("LWAC" or the "Company"), a special purpose acquisition company, announced today that the Company's stockholders have approved all proposals related to the previously announced business combination (the "Business Combination") with eFFECTOR Therapeutics, Inc. ("eFFECTOR") at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC's outstanding shares, voted to approve the Business Combination. LWAC stockholders also voted overwhelmingly to approve the other proposals

      8/24/21 4:47:39 PM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

      SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, announced today the initiation of dosing in the Phase 2a expansion portion of an ongoing Phase 1/2 trial of zotatifin (eFT226) in solid tumors. This followed conclusion of the Phase 1 dose escalation portion of the trial and selection of a recommended Phase 2 dose (RP2D). eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC). Zotatifin will be evaluated both as a single agent and in combination with targ

      8/4/21 8:00:00 AM ET
      $LWAC
      Finance
    • eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

      SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin (eFT226) as an antiviral agent in an outpatient setting for those with mild to moderate COVID-19 disease. This study is sponsored by a $5.0 million cooperative agreement from the Defense Advanced Research Projects Agency (DARPA) and Defense Health Agency (DHA) and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at University of California, San Francisco (UCSF). "Rising case

      7/22/21 8:00:00 AM ET
      $LWAC
      Finance

    $LWAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ehrlich Christopher B

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:22:23 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Bhatt Elizabeth

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:20:18 PM ET
      $LWAC
      Finance
    • SEC Form 4 filed by Smither John W

      4 - eFFECTOR Therapeutics, Inc. (0001828522) (Issuer)

      10/8/21 5:18:52 PM ET
      $LWAC
      Finance